Research advances in rivaroxaban in the treatment of portal vein thrombosis in liver cirrhosis
10.3969/j.issn.1001-5256.2023.07.030
- VernacularTitle:利伐沙班治疗肝硬化门静脉血栓的研究进展
- Author:
Shuang LIU
1
,
2
;
Dongqiang ZHAO
2
Author Information
1. Graduate School of Hebei Medical University, Shijiazhuang 050000, China
2. Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, Hebei Institute of Gastroenterology, Hebei Clinical Research Center for Digestive Diseases, Shijiazhuang 050000, China
- Publication Type:Review
- Keywords:
Liver Cirrhosis;
Rivaroxaban;
Venous Thromboembolism;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(7):1721-1727
- CountryChina
- Language:Chinese
-
Abstract:
Portal vein thrombosis (PVT) is one of the common complications of liver cirrhosis and is associated with the poor prognosis of liver disease. Rivaroxaban, a novel direct oral anticoagulant, exerts an antithrombotic effect by directly acting on the active center of factor Xa to inhibit the generation of thrombin, and it is a new choice for long-term anticoagulant treatment of PVT in liver cirrhosis with the advantages of direct oral administration and no need for international normalized ratio (INR) monitoring. In recent years, more and more clinical studies have shown that rivaroxaban is relatively safe and effective in the treatment of PVT in liver cirrhosis; however, there is still little experience in the application of rivaroxaban in the treatment of PVT in liver cirrhosis in the current clinical practice, and individualized medication regimen remains to be clarified. This article reviews the research advances in rivaroxaban in the treatment of PVT in liver cirrhosis, in order to provide new ideas for the clinical treatment of PVT in liver cirrhosis.
